New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine
(4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperazinyl)Thieno[2,3-D]Pyrimidine or a salt thereof has value in the treatment of fibromyalgia, obesity, weight gain and other conditions.
1 - 15 . (canceled)
16 . A method for the treatment of a condition selected from the group consisting of obesity and weight gain; substance abuse and drug addition; smoking cessation; eating disorders, and obsessive-compulsive disorder; wherein the treatment comprises administering, to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.
17 . The method, according to claim 16 , wherein said condition is obesity and weight gain.
18 . The method, according to claim 16 , wherein said condition is substance abuse and drug addiction.
19 . The method, according to claim 16 , wherein smoking cessation is desired.
20 . The method, according to claim 16 , wherein said condition is an eating disorder.
21 . The method, according to claim 16 , wherein said condition is obsessive-compulsive disorder.
22 . The method, according to claim 16 , wherein the salt is the hydrochloride monohydrate.
23 . A method for the treatment of a condition selected from the group consisting of pre-menstrual syndrome; migraine; nausea and vomiting; chemotherapy or radioactivity-induced emesis; and fatigue; wherein the treatment comprises, administering to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.
24 . The method, according to claim 23 , wherein said condition is pre-menstrual syndrome.
25 . The method, according to claim 23 , wherein said condition is migraine.
26 . The method, according to claim 23 , wherein said condition is nausea and vomiting.
27 . The method, according to claim 23 , wherein said condition is chemotherapy or radioactivity-induced emesis.
28 . The method, according to claim 23 , wherein said condition is fatigue.
29 . The method, according to claim 23 , wherein the salt is the hydrochloride monohydrate.
30 . A method for the treatment of a condition selected from the group consisting of fibromyalgia; Parkinson's disease; stroke; and schizophrenia; wherein the treatment comprises administering, to an individual in need of such treatment, (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof.
31 . The method, according to claim 30 , wherein said condition is fibromyalgia.
32 . The method, according to claim 30 , wherein said condition is Parkinson's disease.
33 . The method, according to claim 30 , wherein said condition is a stroke.
34 . The method, according to claim 30 , wherein said condition is schizophrenia.
35 . The method, according to claim 30 , wherein the salt is the hydrochloride monohydrate.